Literature DB >> 23604132

Systemic inflammatory response syndrome criteria and vancomycin dose requirement in patients with sepsis.

Yuko Shimamoto1, Tsuyoshi Fukuda, Kazuhiko Tanaka, Katsuya Komori, Daikai Sadamitsu.   

Abstract

PURPOSE: Vancomycin has been used in patients with sepsis infected by MRSA and shows large interindividual variability in its dosing. In this observational study the potential influence of sepsis status on the vancomycin dose requirement in relation to systemic inflammatory response syndrome (SIRS) criteria was assessed.
METHODS: From about 250 patients receiving serum vancomycin monitoring from May 2006 to April 2011 at the Osaka National Hospital, 105 adult patients who had been assessed using the SIRS criteria were identified. Patients on chemotherapy or intermittent positive pressure ventilation in whom the SIRS criteria could not accurately evaluate inflammatory status were excluded. Using two vancomycin serum concentrations at peak and trough, individual pharmacokinetic parameters were calculated by the Bayesian estimation method using a two-compartment model. Creatinine clearance rate was estimated by the Cockcroft-Gault formula (eCcr).
RESULTS: Patients with SIRS had a significantly higher vancomycin clearance than those without SIRS, indicating that SIRS patients had a higher elimination capacity. The vancomycin clearance was positively correlated with the SIRS score defined as the number of positive items in the criteria, and negatively with age, except in patients with renal dysfunction. A linear relationship between the vancomycin clearance and eCcr remained even in the supernormal eCcr phase (more than approximately 120 mL/min).
CONCLUSIONS: This study provides a new insight into the need for quick prediction of dose requirement. That is, an increased vancomycin dosage would be needed in patients with a higher SIRS score to maintain the therapeutic target concentration, in particular in those with a high eCcr value.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23604132     DOI: 10.1007/s00134-013-2909-9

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  20 in total

Review 1.  Methicillin-resistant Staphylococcus aureus.

Authors:  W Brumfitt; J Hamilton-Miller
Journal:  N Engl J Med       Date:  1989-05-04       Impact factor: 91.245

Review 2.  Augmented renal clearance: implications for antibacterial dosing in the critically ill.

Authors:  Andrew A Udy; Jason A Roberts; Robert J Boots; David L Paterson; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

3.  Population pharmacokinetics of vancomycin in Japanese adult patients.

Authors:  M Yasuhara; T Iga; H Zenda; K Okumura; T Oguma; Y Yano; R Hori
Journal:  Ther Drug Monit       Date:  1998-04       Impact factor: 3.681

4.  Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection.

Authors:  J D Knudsen; K Fuursted; S Raber; F Espersen; N Frimodt-Moller
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

Review 5.  Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis.

Authors:  Jason A Roberts; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 6.  Implications of augmented renal clearance in critically ill patients.

Authors:  Andrew A Udy; Jason A Roberts; Jeffrey Lipman
Journal:  Nat Rev Nephrol       Date:  2011-07-19       Impact factor: 28.314

7.  Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.

Authors:  Pamela A Moise-Broder; Alan Forrest; Mary C Birmingham; Jerome J Schentag
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

8.  Revised equations for estimated GFR from serum creatinine in Japan.

Authors:  Seiichi Matsuo; Enyu Imai; Masaru Horio; Yoshinari Yasuda; Kimio Tomita; Kosaku Nitta; Kunihiro Yamagata; Yasuhiko Tomino; Hitoshi Yokoyama; Akira Hishida
Journal:  Am J Kidney Dis       Date:  2009-04-01       Impact factor: 8.860

9.  Decreased meropenem levels in Intensive Care Unit patients with augmented renal clearance: benefit of therapeutic drug monitoring.

Authors:  Uwe Tröger; Andreas Drust; Jens Martens-Lobenhoffer; Ivan Tanev; Rüdiger C Braun-Dullaeus; Stefanie M Bode-Böger
Journal:  Int J Antimicrob Agents       Date:  2012-07-11       Impact factor: 5.283

Review 10.  Vancomycin therapy of severe staphylococcal infections.

Authors:  W M Kirby
Journal:  J Antimicrob Chemother       Date:  1984-12       Impact factor: 5.790

View more
  28 in total

Review 1.  Clinical implications of antibiotic pharmacokinetic principles in the critically ill.

Authors:  Andrew A Udy; Jason A Roberts; Jeffrey Lipman
Journal:  Intensive Care Med       Date:  2013-09-18       Impact factor: 17.440

2.  What is new in the use of aminoglycosides in critically ill patients?

Authors:  Dimitrios K Matthaiou; Jan De Waele; George Dimopoulos
Journal:  Intensive Care Med       Date:  2014-07-04       Impact factor: 17.440

3.  Response to: Is vancomycin clearance really correlated with hemoglobin? Arguments that it's not.

Authors:  Masayuki Chuma; Makoto Makishima
Journal:  Eur J Clin Pharmacol       Date:  2019-07-24       Impact factor: 2.953

4.  Clinical measures for increased creatinine clearances and suboptimal antibiotic dosing.

Authors:  Mathias W Pletz; Jeffrey Lipman
Journal:  Intensive Care Med       Date:  2013-04-20       Impact factor: 17.440

5.  Change of teicoplanin loading dose requirement for incremental increases of systemic inflammatory response syndrome score in the setting of sepsis.

Authors:  Takafumi Nakano; Yoshihiko Nakamura; Tohru Takata; Keiichi Irie; Kazunori Sano; Osamu Imakyure; Kenichi Mishima; Koujiro Futagami
Journal:  Int J Clin Pharm       Date:  2016-04-28

6.  The pharmacokinetics of vancomycin in patients with severe acute pancreatitis.

Authors:  Juan He; En-Qiang Mao; Jing Feng; Hui-Ting Jiang; Wan-Hua Yang; Er-Zhen Chen
Journal:  Eur J Clin Pharmacol       Date:  2016-02-23       Impact factor: 2.953

7.  Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial.

Authors:  Jan J De Waele; S Carrette; M Carlier; V Stove; J Boelens; G Claeys; I Leroux-Roels; E Hoste; P Depuydt; J Decruyenaere; A G Verstraete
Journal:  Intensive Care Med       Date:  2013-12-20       Impact factor: 17.440

Review 8.  Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.

Authors:  Nikolas J Onufrak; Alan Forrest; Daniel Gonzalez
Journal:  Clin Ther       Date:  2016-07-20       Impact factor: 3.393

9.  Population Pharmacokinetics and Pharmacodynamics of Meropenem in Critically Ill Pediatric Patients.

Authors:  Jumpei Saito; Kensuke Shoji; Yusuke Oho; Hiroki Kato; Shotaro Matsumoto; Satoshi Aoki; Hidefumi Nakamura; Takanori Ogawa; Mayumi Hasegawa; Akimasa Yamatani; Isao Miyairi
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

10.  Augmented renal clearance in pediatric intensive care: are we undertreating our sickest patients?

Authors:  Evelyn Dhont; Tatjana Van Der Heggen; Annick De Jaeger; Johan Vande Walle; Peter De Paepe; Pieter A De Cock
Journal:  Pediatr Nephrol       Date:  2018-10-29       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.